Intranasal Antifungal Therapy in Patients with Chronic Illness Associated with Mold and Mycotoxins: An Observational Analysis

Joseph Brewer; Dennis Hooper; Shalini Muralidhar

Authors

Joseph Brewer
Dennis Hooper
Shalini Muralidhar

Keywords:

toxic mold, mycotoxin, chronic fatigue syndrome, intranasal antifungal therapy

Abstract

Exposure to mycotoxin producing mold and mycotoxins can be associated with numerous adverse health consequences. We previously reported that patients with chronic illness frequently had a history of prior exposure to water damaged buildings (WDB) and mold. Additionally, the vast majority of these patients had mycotoxins present in the urine. We have postulated that the mycotoxin producing molds were likely harbored internally in the sinuses of these patients. In the present analysis, patients with chronic illness and a positive urine mycotoxin assay were treated with intranasal antifungal therapy, either amphotericin B (AMB) or itraconazole (ITR). AMB was associated with local (nasal) irritation adverse effects (AE) in 34% of the cases, which resulted in discontinuation. In patients that remained on therapy without AE, we found that 94% improved clinically. Additionally, we found that the urine mycotoxin levels decreased substantially in patients that improved on therapy. Similar findings were seen with ITR, however the number of patients treated was much smaller.

Downloads

How to Cite

Intranasal Antifungal Therapy in Patients with Chronic Illness Associated with Mold and Mycotoxins: An Observational Analysis. (2015). Global Journal of Medical Research, 15(K2), 29-33. https://medicalresearchjournal.org/index.php/GJMR/article/view/925

Download Citation

References

J Thrasher, S Crawley (2009) The biocontaminants and complexity of damp indoor spaces: more than what meets the eyes. 25, 583-615.

M Täubel, M Sulyok, V Vishwanath, E Bloom, M Turunen, K Järvi, E Kauhanen, R Krska, A Hyvärinen, L Larsson, A Nevalainen (2011) Co-occurrence of toxic bacterial and fungal secondary metabolites in moisture-damaged indoor environments. 21(5), 368-375.

T Brasel, D Douglas, S Wilson, D Straus (2005) Detection of AirborneStachybotrys chartarumMacrocyclic Trichothecene Mycotoxins on Particulates Smaller than Conidia. 71(1), 114-122.

Joseph Brewer, Jack Thrasher, David Straus, Roberta Madison, Dennis Hooper (2013) Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome. 5(4), 605-617.

J Brewer, J Thrasher, D Hooper (2014) Chronic illness associated with mold and mycotoxins: is naso-sinus fungal biofilm the culprit?. 6, 66-80.

Bristol-Myers Squibb (2009) Fungizone Product Monograph.

J Ponikau, D Sherris, A Weaver, H Kita (2005) Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial. 115, 125-131.

Eilidh Mowat, John Butcher, Sue Lang, Craig Williams, Gordon Ramage (2007) Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. 56(9), 1205-1212.

Emer Reeves, Thomas Murphy, Paul Daly, Kevin Kavanagh (2004) Amphotericin B enhances the synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary pathogen Aspergillus fumigatus. 53(8), 719-725.

Karen Oakley, Caroline Moore, David Denning (1999) Comparison of In Vitro Activity of Liposomal Nystatin against Aspergillus Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole. 43(5), 1264-1266.

Brent Uren, Alkis Psaltis, Peter‐john Wormald (2008) Nasal Lavage With Mupirocin for the Treatment of Surgically Recalcitrant Chronic Rhinosinusitis. 118(9), 1677-1680.

T Le, A Psaltis, L Tan, P Wormold (2008) The efficacy of topical biofilm agents in a sheep model of rhinosinusitis. 22, 560-567.